Featured Article|Articles in Press, 104473

Management of Stable Angina: A Treatment Strategy Mnemonic


      • Coronary artery disease is the underlying cause of stable angina.
      • Lifestyle modifications, evidence-based medications, and revascularization are used to manage coronary artery disease.
      • The impact of stable angina on patients’ quality of life guides treatment strategies.
      • Current guidelines support the use of noninvasive testing to diagnose stable angina.


      Nurse practitioners are well-positioned to diagnose and manage stable angina pectoris by implementing guideline-driven medical interventions. This report presents a mnemonic based on current guidelines to support the nurse practitioner by effectively recalling and using evidence-based treatment plans in clinical practice.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Naghavi M.
        • Wang H.
        • Lozano R.
        • et al.
        Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.
        Lancet. 2015; 385: 117-171
        • Joshi P.H.
        • de Lemos J.A.
        Diagnosis and management of stable angina: a review.
        JAMA. 2021; 325: 1765-1778
        • Sanchis-Gomar F.
        • Perez-Quilis C.
        • Leischik R.
        • et al.
        Epidemiology of coronary heart disease and acute coronary syndrome.
        Ann Transl Med. 2016; 4 (256): 256
        • Kobiyama K.
        • Ley K.
        Atherosclerosis. Circ Res. 2018; 123: 1118-1120
        • Andrews J.
        • Fayad Z.A.
        • Dweck M.R.
        New methods to image unstable atherosclerotic plaques.
        Atherosclerosis. 2018; 272: 118-128
        • Knuuti J.
        • Wijns W.
        • Saraste A.
        • et al.
        2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes.
        Eur Heart J. 2020; 41: 407-477
        • Gulati M.
        • Levy P.D.
        • Mukherjee D.
        • et al.
        • Writing Committee Members
        2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2021; 78: e187-e285
        • Frieling T.
        Non-cardiac chest pain.
        Visc Med. 2018; 34: 92-96
        • Mieres J.H.
        • Heller G.V.
        • Hendel R.C.
        • et al.
        Signs and symptoms of suspected myocardial ischemia in women: results from the What is the Optimal Method for Ischemia Evaluation in Women? trial.
        J Womens Health. 2011; 20: 1261-1268
        • Dagenais G.R.
        • Armstrong P.W.
        • Theroux P.
        • et al.
        Revisiting the Canadian Cardiovascular Society grading of stable angina pectoris after a quarter of a century of use.
        Can J Cardiol. 2022; 18: 941-944
        • Thomas M.
        • Jones P.G.
        • Arnold S.
        • et al.
        Interpretation of the Seattle Angina Questionnaire as an outcome measure in clinical trials and clinical care. A review.
        JAMA Cardiol. 2021; 6: 593-599
        • Chan P.S.
        • Jones P.G.
        • Arnold S.
        • et al.
        Development and validation of a short version of the Seattle angina questionnaire.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 640-647
        • Douglas P.S.
        • Hoffmann U.
        • Patel M.R.
        • et al.
        Outcomes of anatomical versus function testing for coronary artery disease.
        N Engl J Med. 2015; 372: 1291-1300
        • Duncan M.S.
        • Freiberg M.S.
        • Greevy R.A.
        • et al.
        Association of smoking cessation with subsequent risk of cardiovascular disease.
        JAMA. 2019; 322: 642-650
        • Jeong S.
        • Jeon K.H.
        • Shin D.W.
        • et al.
        Smoking cessation, but not reduction, reduces cardiovascular disease incidence.
        Eur Heart J. 2021; 42: 4141-4153
        • Martínez-González M.A.
        • Salas-Salvadó J.
        • Estruch R.
        • et al.
        Benefits of the Mediterranean diet: insights from the PREDIMED Study.
        Prog Cardiovasc Dis. 2015; 58: 50-60
        • Wood A.M.
        • Kaptoge S.
        • Butterworth A.S.
        • et al.
        Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies.
        Lancet. 2018; 391: 1513-1523
        • Khan S.S.
        • Ning H.
        • Wilkins J.T.
        • et al.
        Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity.
        JAMA Cardiol. 2018; 3: 280-287
        • Pack Q.R.
        • Rodriguez-Escudero J.P.
        • Thomas R.J.
        • et al.
        The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis.
        Mayo Clin Proc. 2014; 89: 1368-1377
        • Bangalore S.
        • Bhatt D.L.
        • Steg P.G.
        • et al.
        β-Blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 872-881
        • Peyracchia M.
        • Errigo D.
        • Rapsoseiras R.
        • et al.
        Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results.
        J Cardiovas Med. 2018; 19: 337-343
        • Tarkin J.M.
        • Kaski J.C.
        Nicorandil and long-acting nitrates: vasodilator therapies for the management of chronic stable angina pectoris.
        Eur Cardiol. 2018; 13: 23-28
        • Cruz Rodriguez J.B.
        • Alkhateeb H.
        Beta-blockers, calcium channel blockers, and mortality in stable coronary artery disease.
        Curr Cardiol Rep. 2020; 22: 12
        • Salazar C.A.
        • Basilio Flores J.E.
        • Veramendi Espinoza L.E.
        • et al.
        Ranolazine for stable angina pectoris.
        Cochrane Database Syst Rev. 2017; : CD011747
        • Calcagno S.
        • Infusino F.
        • Salvi N.
        • et al.
        The role of ranolazine for the treatment of residual angina beyond the percutaneous coronary revascularization.
        J Clin Med. 2020; 9: 2110
        • Mehta P.K.
        • Sharma S.
        • Minissian M.
        • et al.
        Ranolazine reduces angina in women with ischemic heart disease: results of an open-label, multicenter trial.
        J Womens Health. 2019; 28: 573-582
        • Jiang J.
        • Li Y.
        • Zhou Y.
        • et al.
        Oral nicorandil reduces ischemic attacks in patients with stable angina: a prospective, multicenter, open-label, randomized, controlled study.
        Int J Cardiol. 2016; 224: 183-187
        • DiFrancesco D.
        Funny channels in the control of cardiac rhythm and mode of action of selective blockers.
        Pharmacol Res. 2006; 53: 399-406
        • Alyavi A.
        • Uzokov J.
        Treatment of stable angina pectoris: focus on the role of calcium antagonists and ACE inhibitors.
        E-journal Cardiol Practice. 2017; 15: 1-12
        • Lexicomp Lexi-Clinical Suite
        [mobile application software].
        • Hoang V.
        • Alam M.
        • Addison D.
        • et al.
        Efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in coronary artery disease without heart failure in the modern statin era: a meta-analysis of randomized-controlled trials.
        Cardiovasc Drugs Ther. 2016; 30: 189-198
        • Fihn S.D.
        • Blankenship J.C.
        • Alexander K.P.
        • et al.
        2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
        J Am Coll Cardiol. 2014; 64: 1929-1949
        • Windecker S.
        • Stortecky S.
        • Stefanini G.G.
        • et al.
        Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis.
        BMJ. 2014; 348: 3859
        • Ybarra L.F.
        • Dautov R.
        • Gibrat C.
        • et al.
        Midterm angina-related quality of life benefits after percutaneous coronary intervention of chronic total occlusions.
        Can J Cardiol. 2017; 33: 1668-1674
        • Hirai T.
        • Grantham J.A.
        • Sapontis J.
        • et al.
        Quality of life changes after chronic total occlusion angioplasty in patients with baseline refractory angina.
        Circ Cardiovasc Interv. 2019; 12e007558
        • Thrombosis Canada
        Acetylsalicylic Acid (ASA).
        • Angiolillo D.J.
        • Franchi F.
        • Waksman R.
        • et al.
        Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing ad hoc PCI.
        J Am Coll Cardiol. 2016; 67: 603-613
        • Cannon C.P.
        • Harrington R.A.
        • James S.
        • et al.
        Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
        Lancet. 2010; 375: 283-293
        • Beygui F.
        • Dillinger J.G.
        • Boccara F.
        • et al.
        Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
        Lancet. 2020; 396: 1737-1744
        • Guan W.
        • Lu H.
        • Yang K.
        Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: a systematic review and meta-analysis (2007-2017).
        Medicine (Baltimore). 2018; 97e12978
        • Connolly S.J.
        • Eikelboom J.W.
        • Bosch J.
        • et al.
        Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
        Lancet. 2018; 391: 205-218
        • Anand S.S.
        • Eikelboom J.W.
        • Dyal L.
        • et al.
        Rivaroxaban plus aspirin in relation to vascular risk in the COMPASS trial.
        J Am Coll Cardiol. 2019; 73: 3271-3280
      1. Thrombosis Canada. Rivaroxaban (Xarelto).
        • Anderson T.J.
        • Grégoire J.
        • Pearson G.J.
        • et al.
        2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.
        Can J Cardiol. 2016; 32: 1263-1282
        • Katoh A.
        • Hattori Y.
        • Yoshikwa N.
        • et al.
        P857: The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins.
        Eur Heart J. 2017; 38 (ehx501.P857)
        • Grundy S.M.
        • Stone N.J.
        • Bailey A.L.
        • et al.
        2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2019; 73: 3168-3209
        • Thondapu V.
        • Kurihara O.
        • Yonetsu T.
        • et al.
        Comparison of rosuvastatin versus atorvastatin for coronary plaque stabilization.
        Am J Cardiol. 2019; 123: 1565-1571


      Mohamed Toufic El-Hussein, RN, PhD, NP, is a professor at the School of Nursing and Midwifery, Faculty of Health Community & Education, Mount Royal University in Calgary, Alberta, Canada, and acute care nurse practitioner, Medical Cardiology Coronary Care Unit at Alberta Health Services, Rockyview Hospital, Calgary, Alberta, Canada, and may be reached at: [email protected]


      Jonah Hakkola, RN, is a registered nurse at Alberta Health Services, Medical Cardiology Unit 66, South Health Campus, Calgary, Alberta, Canada.